Tasquinimod
- Generic Name
- Tasquinimod
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H17F3N2O4
- CAS Number
- 254964-60-8
- Unique Ingredient Identifier
- 756U07KN1R
- Background
The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts
- Indication
Investigated for use/treatment in prostate cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2024-09-20
- Target Recruit Count
- 20
- Registration Number
- NCT06605586
- Locations
- 🇩🇪
DE-Aachen-UKAACHEN, Aachen, Germany
🇳🇱NL-Amsterdam-AmsterdamUMC, Amsterdam, Netherlands
🇳🇱NL-Groningen-UMCG, Groningen, Netherlands
Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
- Conditions
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT06327100
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 34
- Registration Number
- NCT04405167
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT02159950
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 146
- Registration Number
- NCT02057666
- Locations
- 🇨🇳
Beijing Chao-Yang Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Hospital of Ministry of Health, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 201
- Registration Number
- NCT01743469
- Locations
- 🇧🇪
Leuven cancer institute (LKI), Herestraat, Leuven, Belgium
🇧🇪Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
🇨🇦Juravinski Cancer Centre, 699 Concession St, Hamilton, Ontario, Canada
A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 144
- Registration Number
- NCT01732549
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
ðŸ‡ðŸ‡ºBajcsy-Zsilinszky Kórház, Budapest, Hungary
ðŸ‡ðŸ‡ºOrszágos Onkológia Intézet, Budapest, Hungary
The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Andrew J. Armstrong, MD
- Target Recruit Count
- 25
- Registration Number
- NCT01513733
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸Duke Cancer Institute, Durham, North Carolina, United States
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Active Biotech AB
- Target Recruit Count
- 1245
- Registration Number
- NCT01234311
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.